Joinn Laboratories (China) Co (SHSE:603127) Valuation Rank

View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Joinn Laboratories (China) Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

06127:Hong Kong

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Executives

Yao Da Lin	Director
Sun Yun Xia	Director
Zuo Cong Lin	Director
Gao Da Peng	Director
Li Ye	Supervisors
Gu Xiao Lei	Director
Feng Yu Xia	Director
Gu Jing Liang	senior management
Yu Ai Shui	senior management
Yin Li Li	Supervisors
Sun Hui Ye	Supervisors
Gu Mei Fang	Director